Massachusetts is currently home to 3352 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Predicting SSRI Efficacy in Veterans With PTSD
NCT04183205
Recruiting
This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/17/2024
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder
Register for Updates
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
NCT04139902
Recruiting
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma Stage III, Melanoma Stage IV
Register for Updates
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
NCT04097145
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
Register for Updates
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647
Recruiting
This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill with no medicine). This is a blinded study, so neither pat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: HER2-positive Breast Cancer
Register for Updates
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
NCT03824483
Recruiting
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital (Data Collection and Specimen Analysis), Boston, Massachusetts
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Boston Clinical Trials, Boston, Massachusetts
Conditions: Episodic Migraine
Register for Updates
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02977780
Recruiting
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : Abemaciclib Temozolomide (temodar) Neratinib CC115 QBS10072S
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Glioblastoma
Register for Updates
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678
Recruiting
This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety monitoring to ensure the safety of the patients. The initial combination to be investigated is ceralasertib with carboplatin. Th... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/17/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Register for Updates
Molecular and Genetic Studies of Congenital Myopathies
NCT00272883
Recruiting
In the Congenital Myopathy Research Program at Boston Children's Hospital and Harvard Medical School, the researchers are studying the congenital myopathies (neuromuscular diseases present from birth), including central core disease, centronuclear/myotubular myopathy, congenital fiber type disproportion, multiminicore disease, nemaline myopathy, rigid spine muscular dystrophy, SELENON (SEPN1), RYR1 myopathy, ADSS1 (ADSSL) Myopathy and undefined congenital myopathies. The primary goal of the rese... Read More
Gender:
All
Ages:
All
Trial Updated:
06/17/2024
Locations: Genetics Division, Boston Children's Hospital, Boston, Massachusetts
Conditions: Central Core Disease, Centronuclear Myopathy, Congenital Fiber Type Disproportion, Multiminicore Disease, Myotubular Myopathy, Nemaline Myopathy, Rigid Spine Muscular Dystrophy, Undefined Congenital Myopathy
Register for Updates
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
NCT05488340
Recruiting
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an activ... Read More
Gender:
Female
Ages:
Between 18 years and 70 years
Trial Updated:
06/16/2024
Locations: Research Site 120, Boston, Massachusetts
Conditions: Urinary Tract Infections
Register for Updates
Personalized tDCS in Elderly Fallers Study
NCT03814304
Recruiting
The objective of this study is to determine if a four-week, 20-session intervention of personalized transcranial direct current stimulation (tDCS), as compared to sham intervention, improves dual task standing and walking performance (Aim 1), as well as other physical (Aim 2) and cognitive (Aim 3) factors on the causal pathway to falls, in older adults who report two or more falls within the past year and fear of falling again in the future, yet who do not have any acute or over neurological or... Read More
Gender:
All
Ages:
Between 60 years and 100 years
Trial Updated:
06/16/2024
Locations: Hebrew Rehabilitation Center, Roslindale, Massachusetts
Conditions: Accidental Falls, Aging
Register for Updates